- Home
- DYAI vs PSTV Comparison
DYAI vs PSTV Comparison
Compare DYAI & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | PSTV |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 27.5M |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DYAI | PSTV |
|---|---|---|
| Price | $1.19 | $3.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $55.00 |
| AVG Volume (30 Days) | ★ 248.7K | 196.3K |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | $3,090,345.00 | ★ $5,213,000.00 |
| Revenue This Year | $122.79 | $13.20 |
| Revenue Next Year | $100.00 | $261.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $0.13 |
| 52 Week High | $1.35 | $8.00 |
Technical Indicators
Market Signals| Indicator | DYAI | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 36.90 |
| Support Level | $0.76 | $3.70 |
| Resistance Level | $1.29 | $4.51 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 76.66 | 16.05 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).